Instem Life Science Systems, maker of early development safety assessment software, says it will use cash raised in its initial public offering in London to increase its appeal to big pharma. On the radar: acquisitions that target software makers whose product capabilities complement its own. Efficacy and drug behavior in the body are examples. The strategy is to capitalize on the needs of drug developers facing a fragmented solutions supplier community. Article